drugsTreatmentPhase 3

Semaglutide (EVOKE programme)

Semaglutide is FDA-approved for other indications. Alzheimer’s disease use remains investigational in Phase 3 EVOKE studies — not a dementia label.

Existing diabetes or obesity approvals do not equal a dementia indication. Alzheimer’s dosing and benefit are unproven outside trials. Not for self-directed dementia treatment.

See it in action

GLP-1 receptor agonist; Alzheimer’s cognition outcomes under study in EVOKE trials. Already labelled for diabetes/weight — not for dementia.

1. What happens next: the small molecule schematic

How this front works, step by step · animated schematic, not to scale; chosen from the modality "small molecule"

2. Step by step

auto-advancing · hover to pause

1.Semaglutide (EVOKE programme) slips into a pocket on its target.

Modality

small molecule

Mechanism

GLP-1 receptor agonist; Alzheimer’s cognition outcomes under study in EVOKE trials. Already labelled for diabetes/weight — not for dementia.

Brand / code

Ozempic / Rybelsus / Wegovy (other indications)

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Semaglutide (EVOKE programme)

intervention: Semaglutide

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.